Discrepancy between CYP2D6 phenotype and genotype derived from post-mortem dextromethorphan blood level

被引:9
作者
Bailey, B
Daneman, R
Daneman, N
Mayer, JM
Koren, G
机构
[1] Hop St Justine, Dept Pediat, Div Clin Pharmacol & Toxicol, Montreal, PQ H3T 1C5, Canada
[2] Hosp Sick Children, Dept Pediat, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
[3] Ctr Forens Sci, Toronto, ON, Canada
关键词
dextromethorphan; post-mortem blood level; genotype; phenotype; CYP; 2D6;
D O I
10.1016/S0379-0738(00)00142-0
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
Objective: To describe the death of a toddler after a therapeutic dose of dextrometholphan and its investigation. Study design: Case report, cytochrome P450 phenotype and genotype determination in the victim and post-mortem drug redistribution study performed in rats. Results: A 20-month Asian male who received 3 mg of dextromethorphan once at 09:00 h and again at 22:00 h was found dead at 04:35 h. Post-mortem examination showed signs of early bronchopneumonia (bacterial cultures were negative); dextromethorphan and dextrorphan blood concentrations taken from the heart cavity were 500 ng/ml (1.84 mu mol/l) and 200 ng/ml (0.78 mu mol/l), respectively. Despite the dextromethorphan level bring almost 100-fold higher than expected after therapeutic doses, intentional or unintentional overdose was extremely unlikely; other potential causes were investigated. Post-mortem drug redistribution study performed in rats showed that dextromethorphan does not undergo extensive redistribution after death (6+/-5-fold increase) and could not explain the observed dextromethorphan level. The dextromethorphan/dextrorphan concentration ratio of 2.5 found in this toddler was compatible with a slow CYP2D6 metabolizer phenotype. However, the toddler exhibited a fast metabolizer genotype. Potential reasons for this discrepancy are discussed. Conclusion: CYP450 phenotypes derived from post-mortem blood levels should be interpreted with caution and preferably confirmed by a genotype analysis. (C) 2900 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:61 / 70
页数:10
相关论文
共 26 条
[1]   DEXTROMETHORPHAN - AN OVERVIEW OF SAFETY ISSUES [J].
BEM, JL ;
PECK, R .
DRUG SAFETY, 1992, 7 (03) :190-199
[2]  
BENSON WM, 1953, J PHARMACOL EXP THER, V109, P189
[3]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[4]  
Dodds A, 1967, MED J AUSTRALIA, V2, P231
[5]   Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results [J].
Druid, H ;
Holmgren, P ;
Carlsson, B ;
Ahlner, J .
FORENSIC SCIENCE INTERNATIONAL, 1999, 99 (01) :25-34
[6]   CYTOCHROME-P450-DEPENDENT METABOLISM OF DEXTROMETHORPHAN - FETAL AND ADULT STUDIES [J].
JACQZAIGRAIN, E ;
CRESTEIL, T .
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1992, 18 (3-4) :161-168
[7]  
KATONA B, 1986, NEW ENGL J MED, V314, P993
[8]  
Kearns Gregory L., 1995, Current Opinion in Pediatrics, V7, P220, DOI 10.1097/00008480-199504000-00018
[9]   TOXICOLOGICAL FINDINGS IN A DEATH INVOLVING DEXTROMETHORPHAN AND TERFENADINE [J].
KINTZ, P ;
MANGIN, P .
AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY, 1992, 13 (04) :351-352
[10]  
KOREN G, 1992, THER DRUG MONIT, V14, P461